Ionis Total Revenue vs Minority Interest Analysis

IONS Stock

USD 37.99 0.01 0.03%

Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Total Revenue and its Minority Interest accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Total Revenue vs Minority Interest

Total Revenue vs Minority Interest Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Total Revenue account and Minority Interest. At this time, the significance of the direction appears to have pay attention.

The correlation between Ionis Pharmaceuticals' Total Revenue and Minority Interest is -0.78. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Minority Interest in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Total Revenue and Minority Interest is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Ionis Pharmaceuticals are associated (or correlated) with its Minority Interest. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Minority Interest has no effect on the direction of Total Revenue i.e., Ionis Pharmaceuticals' Total Revenue and Minority Interest go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Ionis Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Ionis Pharmaceuticals whose combined shares represent less than 50% of the total outstanding shares issued by Ionis Pharmaceuticals have a minority interest in Ionis Pharmaceuticals.

Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	829M	984M	1.1B	1.2B
Cost Of Revenue	11M	14M	9.1M	8.7M

Total Operating Expenses Cost Of Revenue

Ionis Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Property Plant And Equipment Gross	Short Term Investments	Common Stock	Other Assets
Total Assets		0.85	0.58	0.92	0.73	0.86	-0.16	-0.6	0.68	0.94	0.6	1.0	0.59	0.93	0.95	0.94	0.93	1.0	0.3	0.74	0.52	0.5	0.83	0.96	0.43	0.64
Short Long Term Debt Total	0.85		0.73	0.92	0.3	0.95	0.25	-0.8	0.38	0.67	0.14	0.85	0.46	0.97	0.92	0.81	0.97	0.87	0.22	0.7	0.5	0.61	0.97	0.83	0.37	0.29
Other Current Liab	0.58	0.73		0.65	0.11	0.65	0.36	-0.53	0.11	0.54	0.19	0.58	0.22	0.69	0.57	0.5	0.69	0.58	-0.46	0.42	0.41	0.35	0.71	0.56	0.23	0.21
Total Current Liabilities	0.92	0.92	0.65		0.43	0.93	0.18	-0.8	0.4	0.79	0.33	0.91	0.5	0.97	0.92	0.89	0.98	0.93	0.34	0.72	0.67	0.61	0.91	0.91	0.43	0.33
Total Stockholder Equity	0.73	0.3	0.11	0.43		0.38	-0.75	-0.04	0.9	0.83	0.87	0.73	0.59	0.43	0.6	0.67	0.43	0.7	0.24	0.5	0.18	0.09	0.26	0.67	0.32	0.86
Property Plant And Equipment Net	0.86	0.95	0.65	0.93	0.38		0.17	-0.84	0.43	0.72	0.18	0.86	0.57	0.94	0.92	0.88	0.94	0.88	0.32	0.81	0.5	0.49	0.94	0.85	0.52	0.25
Net Debt	-0.16	0.25	0.36	0.18	-0.75	0.17		-0.38	-0.8	-0.31	-0.62	-0.17	-0.4	0.17	-0.06	-0.18	0.17	-0.14	-0.09	-0.11	0.09	0.3	0.33	-0.1	-0.13	-0.64
Retained Earnings	-0.6	-0.8	-0.53	-0.8	-0.04	-0.84	-0.38		-0.12	-0.42	0.12	-0.6	-0.62	-0.78	-0.64	-0.76	-0.78	-0.62	-0.27	-0.8	-0.7	-0.47	-0.81	-0.54	-0.71	0.07
Cash	0.68	0.38	0.11	0.4	0.9	0.43	-0.8	-0.12		0.72	0.69	0.69	0.66	0.44	0.63	0.67	0.43	0.67	0.23	0.53	0.23	0.09	0.28	0.61	0.35	0.79
Non Current Assets Total	0.94	0.67	0.54	0.79	0.83	0.72	-0.31	-0.42	0.72		0.81	0.93	0.57	0.78	0.82	0.87	0.78	0.92	0.16	0.66	0.48	0.31	0.64	0.91	0.42	0.72
Non Currrent Assets Other	0.6	0.14	0.19	0.33	0.87	0.18	-0.62	0.12	0.69	0.81		0.59	0.36	0.3	0.39	0.48	0.3	0.56	-0.03	0.26	0.25	0.02	0.1	0.57	0.16	0.83
Cash And Short Term Investments	1.0	0.85	0.58	0.91	0.73	0.86	-0.17	-0.6	0.69	0.93	0.59		0.6	0.93	0.95	0.94	0.93	1.0	0.3	0.74	0.52	0.49	0.83	0.95	0.43	0.65
Common Stock Shares Outstanding	0.59	0.46	0.22	0.5	0.59	0.57	-0.4	-0.62	0.66	0.57	0.36	0.6		0.49	0.52	0.78	0.49	0.59	0.2	0.88	0.53	0.13	0.42	0.46	0.86	0.38
Non Current Liabilities Total	0.93	0.97	0.69	0.97	0.43	0.94	0.17	-0.78	0.44	0.78	0.3	0.93	0.49		0.94	0.88	1.0	0.94	0.28	0.73	0.56	0.61	0.96	0.89	0.39	0.4
Other Current Assets	0.95	0.92	0.57	0.92	0.6	0.92	-0.06	-0.64	0.63	0.82	0.39	0.95	0.52	0.94		0.89	0.94	0.96	0.38	0.73	0.42	0.54	0.89	0.95	0.33	0.5
Other Stockholder Equity	0.94	0.81	0.5	0.89	0.67	0.88	-0.18	-0.76	0.67	0.87	0.48	0.94	0.78	0.88	0.89		0.88	0.94	0.35	0.88	0.64	0.44	0.79	0.86	0.7	0.51
Total Liab	0.93	0.97	0.69	0.98	0.43	0.94	0.17	-0.78	0.43	0.78	0.3	0.93	0.49	1.0	0.94	0.88		0.94	0.29	0.73	0.58	0.61	0.96	0.9	0.4	0.39
Total Current Assets	1.0	0.87	0.58	0.93	0.7	0.88	-0.14	-0.62	0.67	0.92	0.56	1.0	0.59	0.94	0.96	0.94	0.94		0.32	0.75	0.52	0.53	0.85	0.95	0.42	0.62
Short Term Debt	0.3	0.22	-0.46	0.34	0.24	0.32	-0.09	-0.27	0.23	0.16	-0.03	0.3	0.2	0.28	0.38	0.35	0.29	0.32		0.29	0.1	0.33	0.24	0.33	0.11	-0.01
Intangible Assets	0.74	0.7	0.42	0.72	0.5	0.81	-0.11	-0.8	0.53	0.66	0.26	0.74	0.88	0.73	0.73	0.88	0.73	0.75	0.29		0.52	0.29	0.72	0.64	0.81	0.34
Accounts Payable	0.52	0.5	0.41	0.67	0.18	0.5	0.09	-0.7	0.23	0.48	0.25	0.52	0.53	0.56	0.42	0.64	0.58	0.52	0.1	0.52		0.33	0.43	0.47	0.56	0.1
Net Receivables	0.5	0.61	0.35	0.61	0.09	0.49	0.3	-0.47	0.09	0.31	0.02	0.49	0.13	0.61	0.54	0.44	0.61	0.53	0.33	0.29	0.33		0.57	0.48	0.05	0.1
Property Plant And Equipment Gross	0.83	0.97	0.71	0.91	0.26	0.94	0.33	-0.81	0.28	0.64	0.1	0.83	0.42	0.96	0.89	0.79	0.96	0.85	0.24	0.72	0.43	0.57		0.81	0.39	0.28
Short Term Investments	0.96	0.83	0.56	0.91	0.67	0.85	-0.1	-0.54	0.61	0.91	0.57	0.95	0.46	0.89	0.95	0.86	0.9	0.95	0.33	0.64	0.47	0.48	0.81		0.29	0.57
Common Stock	0.43	0.37	0.23	0.43	0.32	0.52	-0.13	-0.71	0.35	0.42	0.16	0.43	0.86	0.39	0.33	0.7	0.4	0.42	0.11	0.81	0.56	0.05	0.39	0.29		0.15
Other Assets	0.64	0.29	0.21	0.33	0.86	0.25	-0.64	0.07	0.79	0.72	0.83	0.65	0.38	0.4	0.5	0.51	0.39	0.62	-0.01	0.34	0.1	0.1	0.28	0.57	0.15

Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.2B	2.4B	2.6B	2.5B	3.0B	3.1B
Short Long Term Debt Total	710M	749M	1.2B	1.3B	1.5B	1.5B
Other Current Liab	136.9M	(128.4M)	127.6M	195.5M	217.8M	228.7M
Total Current Liabilities	273M	290M	241M	312M	448.1M	470.5M
Total Stockholder Equity	1.5B	843M	772M	573M	386.7M	265.7M
Property Plant And Equipment Net	154M	181M	178M	256M	242.9M	255.1M
Net Debt	(1.8B)	(1.1B)	(954M)	(642M)	1.1B	1.1B
Retained Earnings	(707.5M)	(1.2B)	(1.2B)	(1.4B)	(1.8B)	(1.7B)
Cash	2.5B	1.9B	2.1B	2.0B	399.3M	534.5M
Non Current Assets Total	512M	260M	267M	331M	348.2M	365.6M
Non Currrent Assets Other	358M	51.1M	60.0M	34.6M	62.3M	34.5M
Cash And Short Term Investments	2.5B	1.9B	2.1B	2.0B	2.3B	2.4B
Common Stock Shares Outstanding	142.9M	139.6M	141.0M	141.8M	143.2M	83.9M
Liabilities And Stockholders Equity	3.2B	2.4B	2.6B	2.5B	3.0B	3.1B
Non Current Liabilities Total	1.3B	1.3B	1.6B	1.6B	2.2B	2.3B
Other Current Assets	158M	162M	168M	190M	184.4M	193.7M
Other Stockholder Equity	2.2B	2.1B	2.0B	2.1B	2.2B	2.3B
Total Liab	1.5B	1.5B	1.8B	2.0B	2.6B	2.7B
Total Current Assets	2.7B	2.1B	2.3B	2.2B	2.6B	2.8B
Short Term Debt	2.0M	293.2M	3.5M	7.5M	53.2M	55.8M
Intangible Assets	24.0M	25.7M	27.9M	29.0M	33.4M	24.2M
Accounts Payable	16.1M	17.2M	11.9M	17.9M	26.0M	27.3M
Net Receivables	63M	76M	62M	26M	97.8M	102.7M
Property Plant And Equipment Gross	153.7M	181.1M	280.7M	256M	339.7M	356.7M
Accumulated Other Comprehensive Income	(25.3M)	(21.1M)	(32.7M)	(57.5M)	(32.6M)	(31.0M)
Short Term Investments	1.8B	1.5B	1.2B	1.7B	1.9B	2.0B
Other Assets	310.6M	78.0M	319M	35.0M	40.2M	57.3M
Long Term Debt	770.0M	515.7M	1.2B	1.2B	1.2B	1.3B
Property Plant Equipment	153.7M	181.1M	178.1M	74.3M	85.4M	79.6M
Other Liab	490.1M	424M	352M	287.8M	330.9M	170.0M
Current Deferred Revenue	118M	108M	98M	91M	151.1M	158.7M
Inventory	18.2M	22.0M	24.8M	22.0M	28.4M	29.8M
Net Tangible Assets	1.4B	815.4M	742.7M	572.9M	658.8M	531.9M
Retained Earnings Total Equity	(707.5M)	(1.2B)	(1.2B)	(1.4B)	(1.3B)	(1.4B)
Long Term Debt Total	770.0M	515.7M	1.2B	1.2B	1.4B	1.4B
Capital Surpluse	2.2B	2.1B	2.0B	2.1B	2.4B	1.7B

When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports:

How To Invest In Ionis

Details

Is Ionis Stock a good investment?

Details

What is Ionis Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Ionis Stock analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.44)

Earnings Share

(2.67)

Revenue Per Share

5.397

Quarterly Revenue Growth

(0.08)

Return On Assets

(0.08)

The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ionis Total Revenue vs Minority Interest Analysis

Total Revenue vs Minority Interest

Total Revenue vs Minority Interest Correlation Analysis

Correlation Coefficient

Total Revenue

Minority Interest

Ionis Pharmaceuticals fundamental ratios Correlations

Ionis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ionis Pharmaceuticals fundamental ratios Accounts

Complementary Tools for Ionis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Total Liab	+ 0.98	Total Current Liabilities
Non Current Liabilities Total	+ 0.97	Short Long Term Debt Total

Retained Earnings	- 0.84	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.81	Retained Earnings
Intangible Assets	- 0.8	Retained Earnings
Cash	- 0.8	Net Debt
Retained Earnings	- 0.8	Total Current Liabilities
Retained Earnings	- 0.8	Short Long Term Debt Total